Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Angiotensin II Causes β-Cell Dysfunction Through an ER Stress-Induced Proinflammatory Response.

Endocrinology | 2017

The metabolic syndrome is associated with an increase in the activation of the renin angiotensin system, whose inhibition reduces the incidence of new-onset diabetes. Importantly, angiotensin II (AngII), independently of its vasoconstrictor action, causes β-cell inflammation and dysfunction, which may be an early step in the development of type 2 diabetes. The aim of this study was to determine how AngII causes β-cell dysfunction. Islets of Langerhans were isolated from C57BL/6J mice that had been infused with AngII in the presence or absence of taurine-conjugated ursodeoxycholic acid (TUDCA) and effects on endoplasmic reticulum (ER) stress, inflammation, and β-cell function determined. The mechanism of action of AngII was further investigated using isolated murine islets and clonal β cells. We show that AngII triggers ER stress, an increase in the messenger RNA expression of proinflammatory cytokines, and promotes β-cell dysfunction in murine islets of Langerhans both in vivo and ex vivo. These effects were significantly attenuated by TUDCA, an inhibitor of ER stress. We also show that AngII-induced ER stress is required for the increased expression of proinflammatory cytokines and is caused by reactive oxygen species and IP3 receptor activation. These data reveal that the induction of ER stress is critical for AngII-induced β-cell dysfunction and indicates how therapies that promote ER homeostasis may be beneficial in the prevention of type 2 diabetes.

Pubmed ID: 28938442 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ATF-4 (D4B8) Rabbit mAb (antibody)

RRID:AB_2616025

This monoclonal targets ATF-4

View all literature mentions

CHOP (L63F7) Mouse mAb (antibody)

RRID:AB_2089254

This monoclonal targets CHOP

View all literature mentions

eIF2alpha (D7D3) XP Rabbit mAb (antibody)

RRID:AB_10692650

This monoclonal targets eIF2alpha

View all literature mentions

PERK (D11A8) Rabbit mAb (antibody)

RRID:AB_10841299

This monoclonal targets PERK (D11A8) Rabbit mAb

View all literature mentions

IRE1 (phospho S724) antibody [EPR5253] (antibody)

RRID:AB_11001365

This monoclonal targets IRE1 (phospho S724) antibody [EPR5253]

View all literature mentions

IRE1 (phospho S724) antibody [EPR5253] (antibody)

RRID:AB_11001365

This monoclonal targets IRE1 (phospho S724) antibody [EPR5253]

View all literature mentions

PERK (D11A8) Rabbit mAb (antibody)

RRID:AB_10841299

This monoclonal targets PERK (D11A8) Rabbit mAb

View all literature mentions

CHOP (L63F7) Mouse mAb (antibody)

RRID:AB_2089254

This monoclonal targets CHOP

View all literature mentions

eIF2alpha (D7D3) XP Rabbit mAb (antibody)

RRID:AB_10692650

This monoclonal targets eIF2alpha

View all literature mentions

ATF-4 (D4B8) Rabbit mAb (antibody)

RRID:AB_2616025

This monoclonal targets ATF-4

View all literature mentions